23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; offers non-controlled medications for treatment of acute and chronic conditions; and provides Ozempic and Wegovy through its weight loss program, offering consumers with access to affordable weight management care. In addition, the company provides research services. 23andMe Holding Co. was founded in 2006 and is headquartered in San Francisco, California.
U.S. Market Performance
7D7 Days: -2.7%
3M3 Months: 10.1%
1Y1 Year: 17.7%
YTDYear to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.